Hypothesis

Elevated carotid‑femoral pulse wave velocity (cfPWV) reflects increased arterial stiffness that transmits heightened pulsatile stress to the microvasculature of the gut wall. This mechanotransduction activates endothelial Piezo1 channels, driving local superoxide production and reducing nitric oxide (NO) bioavailability in intestinal endothelial cells. The resulting gut endothelial dysfunction increases permeability, allowing bacterial translocation and endotoxin influx, which fuels systemic inflammation (SASP amplification) and worsens endothelial NO uncoupling in the vasculature. Consequently, the gut‑vascular axis creates a self‑reinforcing loop that accelerates frailty through impaired muscle perfusion and cognitive decline via heightened neuroinflammation.

Mechanistic Rationale

• Piezo1‑dependent NO scavenging: Stretch‑activated Piezo1 channels, known to be upregulated in aged endothelium, convert mechanical strain into Ca2+ influx that stimulates NADPH oxidase (NOX2) and superoxide generation, scavenging NO (source).
• Gut barrier breach: Superoxide‑mediated nitrosylation of tight‑ junction proteins (occludin, claudin‑5) increases paracellular flux, measurable by plasma zonulin or LPS‑binding protein (source).
• Inflammatory amplification: Circulating LPS engages TLR4 on endothelial and senescent cells, boosting IL‑6, IL-1β and SASP factors, which further suppress eNOS activity and promote ADMA accumulation (source).
• Functional outcomes: Reduced muscle perfusion limits oxygen and nutrient delivery, lowering grip strength and gait speed; simultaneous neuroinflammatory signaling disrupts hippocampal LTP, exacerbating memory decline (source).

Testable Predictions

1. In older adults, cfPWV will positively correlate with plasma zonulin/LPS levels and inversely with intestinal endothelial NO metabolites (nitrite/nitrate) after adjusting for age and blood pressure.
2. Experimental induction of arterial stiffness (e.g., angiotensin II infusion in aged mice) will increase gut permeability and circulating endotoxin within 2 weeks, preceding rises in systemic IL-6 and SASP markers.
3. Pharmacological blockade of Piezo1 (GsMTx4) or targeted delivery of NO donors to the gut endothelium will reduce LPS translocation, lower inflammatory cytokines, and improve grip strength and memory performance in stiff‑artery models.
4. Senolytic treatment that clears vascular senescent cells will attenuate the gut‑vascular loop only when combined with Piezo1 inhibition, indicating that both cellular senescence and mechanotransduction are required for the feed‑forward effect.

Falsifiability

If cfPWV shows no association with gut permeability markers, or if Piezo1 inhibition fails to modify LPS levels or functional outcomes despite reducing arterial stiffness, the hypothesis would be refuted. Likewise, a lack of improvement in frailty or cognition after combined senolytic‑Plus‑Piezo1 blockade would challenge the proposed mechanistic link.

Implications

Demonstrating a gut‑vascular mechanotransduction pathway would shift therapeutic focus from isolated vascular repair to integrated organ‑axis interventions, combining mechanosensitive inhibitors, gut‑targeted NO restoration, and senolytics to break the cycle that drives arterial stiffness‑related frailty and cognitive decline.